Hongmei Mo

Summary

Affiliation: Abbott Laboratories
Country: USA

Publications

  1. pmc In vitro antiviral interaction of lopinavir with other protease inhibitors
    Akhteruzzaman Molla
    Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064, USA
    Antimicrob Agents Chemother 46:2249-53. 2002
  2. ncbi Antiviral interactions of an HCV polymerase inhibitor with an HCV protease inhibitor or interferon in vitro
    Gennadiy Koev
    Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Antiviral Res 73:78-83. 2007
  3. ncbi Expression of recombinant baculovirus carrying Schistosoma japonicum 26 ku GST in mammalian cells
    Guangqing Yu
    Department of Parasitology, School of Basic Medical Sciences, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
    J Huazhong Univ Sci Technolog Med Sci 26:265-8. 2006
  4. pmc Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication
    Hongmei Mo
    Global Pharmaceutical Research and Development, Department R4CQ, Building AP52N, Abbott Laboratories, 200 Abbott Park Road, Abbott Park, IL 60064 6217, USA
    Antimicrob Agents Chemother 51:732-5. 2007
  5. ncbi Inhibitors of HCV NS5B polymerase: synthesis and structure-activity relationships of unsymmetrical 1-hydroxy-4,4-dialkyl-3-oxo-3,4-dihydronaphthalene benzothiadiazine derivatives
    A Chris Krueger
    Infectious Disease Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Bioorg Med Chem Lett 17:2289-92. 2007
  6. pmc Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates
    Hongmei Mo
    Department R47D, Building AP52N, Abbott Laboratories, 200 Abbott Park Rd, Abbott Park, IL 60064 6217, USA
    J Virol 79:3329-38. 2005
  7. ncbi Characterization of resistant HIV variants generated by in vitro passage with lopinavir/ritonavir
    Hongmei Mo
    Global Pharmaceutical Research Development, Department R47D, Abbott Laboratories, Building AP52N, 200 Abbott Park Road, Abbott Park, IL 60064 6217, USA
    Antiviral Res 59:173-80. 2003
  8. pmc Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro
    Hongmei Mo
    Antiviral Research, Abbott Laboratories Global Pharmaceutical Research and Development, Abbott Park, Illinois, USA
    Antimicrob Agents Chemother 49:4305-14. 2005
  9. pmc Complementation in cells cotransfected with a mixture of wild-type and mutant human immunodeficiency virus (HIV) influences the replication capacities and phenotypes of mutant variants in a single-cycle HIV resistance assay
    Hongmei Mo
    Global Pharmaceutical Research and Development, Abbott Laboratories, 200 Abbott Park Rd, Abbott Park, IL 60064 6217, USA
    J Clin Microbiol 42:4169-74. 2004
  10. ncbi Conserved residues in the coiled-coil pocket of human immunodeficiency virus type 1 gp41 are essential for viral replication and interhelical interaction
    Hongmei Mo
    Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Virology 329:319-27. 2004

Detail Information

Publications27

  1. pmc In vitro antiviral interaction of lopinavir with other protease inhibitors
    Akhteruzzaman Molla
    Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064, USA
    Antimicrob Agents Chemother 46:2249-53. 2002
    ..More importantly, the observed in vitro synergy between lopinavir and saquinavir provides a theoretical basis for the clinical exploration of a novel regimen of lopinavir-ritonavir and saquinavir...
  2. ncbi Antiviral interactions of an HCV polymerase inhibitor with an HCV protease inhibitor or interferon in vitro
    Gennadiy Koev
    Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Antiviral Res 73:78-83. 2007
    ..However, a combination therapy with polymerase inhibitor has the potential to improve the efficacy of IFN or a protease inhibitor alone in vivo, due to the lower likelihood of resistance development...
  3. ncbi Expression of recombinant baculovirus carrying Schistosoma japonicum 26 ku GST in mammalian cells
    Guangqing Yu
    Department of Parasitology, School of Basic Medical Sciences, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
    J Huazhong Univ Sci Technolog Med Sci 26:265-8. 2006
    ..24 x 10(8). Western blot demonstrated that recombinant baculovirus could express 26 ku GST in BHK cells. It was concluded that Sj26 recombinant baculovirus was successfully constructed, and the 26 ku GST was expressed in mammalian cells...
  4. pmc Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication
    Hongmei Mo
    Global Pharmaceutical Research and Development, Department R4CQ, Building AP52N, Abbott Laboratories, 200 Abbott Park Road, Abbott Park, IL 60064 6217, USA
    Antimicrob Agents Chemother 51:732-5. 2007
    ....
  5. ncbi Inhibitors of HCV NS5B polymerase: synthesis and structure-activity relationships of unsymmetrical 1-hydroxy-4,4-dialkyl-3-oxo-3,4-dihydronaphthalene benzothiadiazine derivatives
    A Chris Krueger
    Infectious Disease Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Bioorg Med Chem Lett 17:2289-92. 2007
    ..Structure-activity relationship patterns for this class of compounds are discussed. It was found that the saturated alkane dialkyl units provided the most active analogs...
  6. pmc Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates
    Hongmei Mo
    Department R47D, Building AP52N, Abbott Laboratories, 200 Abbott Park Rd, Abbott Park, IL 60064 6217, USA
    J Virol 79:3329-38. 2005
    ....
  7. ncbi Characterization of resistant HIV variants generated by in vitro passage with lopinavir/ritonavir
    Hongmei Mo
    Global Pharmaceutical Research Development, Department R47D, Abbott Laboratories, Building AP52N, 200 Abbott Park Road, Abbott Park, IL 60064 6217, USA
    Antiviral Res 59:173-80. 2003
    ....
  8. pmc Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro
    Hongmei Mo
    Antiviral Research, Abbott Laboratories Global Pharmaceutical Research and Development, Abbott Park, Illinois, USA
    Antimicrob Agents Chemother 49:4305-14. 2005
    ..Furthermore, the dually resistant mutants displayed significantly reduced replication capacities compared to the wild-type replicon. These findings provide strategic guidance for the future treatment of HCV infection...
  9. pmc Complementation in cells cotransfected with a mixture of wild-type and mutant human immunodeficiency virus (HIV) influences the replication capacities and phenotypes of mutant variants in a single-cycle HIV resistance assay
    Hongmei Mo
    Global Pharmaceutical Research and Development, Abbott Laboratories, 200 Abbott Park Rd, Abbott Park, IL 60064 6217, USA
    J Clin Microbiol 42:4169-74. 2004
    ..These findings suggest that the RC and susceptibility of plasma isolates from patients who are off therapy or not adherent to treatment, in which WT virus may expand to significant levels, should be interpreted with caution...
  10. ncbi Conserved residues in the coiled-coil pocket of human immunodeficiency virus type 1 gp41 are essential for viral replication and interhelical interaction
    Hongmei Mo
    Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Virology 329:319-27. 2004
    ..In addition, our data indicate that the novel fluorescence polarization assay described in this study could be valuable in screening for inhibitors that block the interhelical interaction and HIV entry...
  11. ncbi A replicon-based shuttle vector system for assessing the phenotype of HCV NS5B polymerase genes isolated from patient populations
    Tim Middleton
    Abbott Laboratories, Global Pharmaceutical Research and Development, Department R4CQ, AP52N, 200 Abbott Park Road, Abbott Park, IL 60064, USA
    J Virol Methods 145:137-45. 2007
    ..This approach provides a means to assess variation in antiviral efficacy, and to predict possible responses in a clinical setting...
  12. ncbi Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitro
    Liangjun Lu
    Abbott Laboratories, Global Pharmaceutical Research and Development, Abbott Park, IL 60064, USA
    Antiviral Res 76:93-7. 2007
    ..These findings provide a strategic guide for the future development of non-nucleoside inhibitors of HCV NS5B polymerase...
  13. doi 2-Pyridyl P1'-substituted symmetry-based human immunodeficiency virus protease inhibitors (A-792611 and A-790742) with potential for convenient dosing and reduced side effects
    David A DeGoey
    Antiviral Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064, USA
    J Med Chem 52:2571-86. 2009
    ..X-ray crystallographic analyses of the new cores were used to examine differences in their binding modes. The antiviral activity of the compounds against protease inhibitor resistant strains of HIV was also determined...
  14. ncbi Identification of host genes involved in hepatitis C virus replication by small interfering RNA technology
    Teresa I Ng
    Global Pharmaceutical Research and Development, Antiviral Research, Abbott Laboratories, 200 Abbott Park Road, Abbott Park, IL 60064, USA
    Hepatology 45:1413-21. 2007
    ..Of interest, some of these genes are members of the tumor necrosis factor/lymphotoxin signaling pathway...
  15. doi Novel hepatitis C virus replicon inhibitors: synthesis and structure-activity relationships of fused pyrimidine derivatives
    A Chris Krueger
    Abbott Labs, Global Pharmaceutical Research and Development, Abbott Park, IL 60064, USA
    Bioorg Med Chem Lett 22:2212-5. 2012
    ..The synthesis of several pyrido[2,3-d]pyrimidine and pyrimido[4,5-d]pyrimidine analogs is described with one such analog possessing subnanomolar potency in both genotype 1a and 1b cell culture HCV replicon assays...
  16. doi Hepatitis C NS5B polymerase inhibitors: functional equivalents for the benzothiadiazine moiety
    Douglas K Hutchinson
    Department of Antiviral Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Bioorg Med Chem Lett 21:1876-9. 2011
    ..Several of these compounds exhibited potent activity in enzymatic and replicon assays...
  17. pmc Evolution of resistant M414T mutants among hepatitis C virus replicon cells treated with polymerase inhibitor A-782759
    Liangjun Lu
    Global Pharmaceutical Research and Development, Abbott Laboratories, GPRD R4CQ, 200 Abbott Park Rd, Abbott Park, IL 60064, USA
    Antimicrob Agents Chemother 51:1889-96. 2007
    ....
  18. pmc Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro
    Liangjun Lu
    Antiviral Research, Abbott Laboratories, Global Pharmaceutical Research and Development, Abbott Park, IL 60064 6217, USA
    Antimicrob Agents Chemother 48:2260-6. 2004
    ..These findings, in addition to the three-dimensional structure analysis of the NS3/NS4A serine protease inhibitor complex, provide a strategic guide for the development of next-generation inhibitors of HCV NS3/NS4A serine protease...
  19. pmc In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir
    Sherie Masse
    Antiviral Research, Global Pharmaceutical Research and Development, AP52N 1 Rm 1133, 200 Abbott Park Road, Abbott Park, IL 60064, USA
    Antimicrob Agents Chemother 51:3075-80. 2007
    ..In contrast, this mutant retained wild-type susceptibility to other PIs and appeared to be hypersusceptible to atazanavir and saquinavir...
  20. ncbi Inhibitors of HCV NS5B polymerase: synthesis and structure-activity relationships of N-alkyl-4-hydroxyquinolon-3-yl-benzothiadiazine sulfamides
    A Chris Krueger
    Infectious Disease Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Bioorg Med Chem Lett 16:3367-70. 2006
    ..Substituted N-alkyl-4-hydroxyquinolon-3-yl-benzothiadiazine sulfamides were investigated as inhibitors of genotype 1 HCV polymerase. Structure-activity relationship patterns for this class of compounds are discussed...
  21. ncbi Synthesis, antiviral activity, and pharmacokinetic evaluation of P3 pyridylmethyl analogs of oximinoarylsulfonyl HIV-1 protease inhibitors
    John T Randolph
    Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Bioorg Med Chem 14:4035-46. 2006
    ..The 3-pyridylmethyl analog 30 gave the best overall exposure (rat AUC=7.1 microg h/mL and dog AUC=4.9 microg h/mL), however, this compound was found to be a potent inhibitor of cytochrome P450 3A (Ki=2.4 nM)...
  22. doi Non-peptide entry inhibitors of HIV-1 that target the gp41 coiled coil pocket
    Kent D Stewart
    Pharmaceutical Discovery Division, Abbott Laboratories, 100 Abbott Park Rd, R46Y, AP10, Abbott Park, IL 60064 6098, United States
    Bioorg Med Chem Lett 20:612-7. 2010
    ..Structural work on the gp41/benzamide 1 complex was determined by NMR spectroscopy using a designed model peptide system that mimics an open pocket of the fusogenic form of the protein...
  23. ncbi Synthesis and SAR of novel 1,1-dialkyl-2(1H)-naphthalenones as potent HCV polymerase inhibitors
    Todd D Bosse
    Infectious Disease Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Bioorg Med Chem Lett 18:568-70. 2008
    ..This investigation led to the discovery of potent inhibitors of the hepatitis C virus at low nanomolar concentrations in both enzymatic and cell-based HCV genotype 1a assays...
  24. ncbi Replication efficiency of chimeric replicon containing NS5A-5B genes derived from HCV-infected patient sera
    Rakesh L Tripathi
    Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Antiviral Res 73:40-9. 2007
    ..The findings also demonstrate the utility of the shuttle vector system to test patient-derived gene sequences for sensitivity to IFN-alpha and to small molecule inhibitors...
  25. ncbi Synthesis and activity of N-acyl azacyclic urea HIV-1 protease inhibitors with high potency against multiple drug resistant viral strains
    Chen Zhao
    GPRD, Abbott Laboratories, Abbott Park, IL 60064 6123, USA
    Bioorg Med Chem Lett 15:5499-503. 2005
    ..The extensive SAR study has yielded a series of N-acyl azacyclic ureas (II), which are highly potent against both wild-type and multiple PI-resistant viral strains...
  26. ncbi Inhibitors of HCV NS5B polymerase: synthesis and structure-activity relationships of N-1-heteroalkyl-4-hydroxyquinolon-3-yl-benzothiadiazines
    John K Pratt
    Infectious Disease Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Bioorg Med Chem Lett 15:1577-82. 2005
    ..The most potent inhibitors contained small alkyl or carbocyclic substituents and exhibited IC50's of 50-100 and 200-400 nM against genotype 1b and 1a HCV polymerase, respectively...
  27. ncbi Inhibition of human immunodeficiency virus type I integrase by naphthamidines and 2-aminobenzimidazoles
    Tim Middleton
    Department R47D, Global Pharmaceutical Research and Development, Abbott Laboratories, 200 Abbott Park Rd, Abbott Park, IL 60064 6217, USA
    Antiviral Res 64:35-45. 2004
    ..These two classes of compounds represent potential starting points for the development of new classes of integrase inhibitors...